| ²é¿´: 1391 | »Ø¸´: 3 | ||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||
bqchen½ð³æ (СÓÐÃûÆø)
|
[ÇóÖú]
ŵ·úɳÐǽºÄÒºÍÄáȺµØÆ½Æ¬µÄÉúÎïÒ©¼Áѧ·ÖÀà
|
|
|
´óÏÀÃǰïæ²éÏ ŵ·úɳÐǽºÄÒ ºÍ ÄáȺµØÆ½Æ¬ µÄÉúÎïÒ©¼Áѧ·ÖÀà¡£ ÕâÁ½¸öÆ·ÖÖµÄÉúÎïÒ©¼Áѧ·ÖÀà ²»ÔÚÕâÁ½¸öÎļþÀïÃæ£ºÊÀ½çÎÀÉú×éÖ¯·¢²¼µÄBCS·ÖÀà 2006 ºÍ NICHDºÍÃÀ¹úʳƷҩƷ¹ÜÀí¾ÖÑо¿¹éÄɵÄBCS·ÖÀࣨ2011Ä꣩¡£ ûÓÐÉúÎïÒ©¼Áѧ·ÖÀàµÄ»°£¬Ò²Çë°ïæÕÒÏÂËûÃǵÄÈܽâÐÔ¡£ ²»Ê¤¸Ð¼¤£¡£¡£¡ |
» ²ÂÄãϲ»¶
¹è½ºÖù¿ÉÒÔÓô¿¶þÂȼ×ÍéÏ´ÍÑÂð
ÒѾÓÐ18È˻ظ´
Çó¹ºÊ±¼ä³¤Ò»Ð©µÄÏõËáîÊ
ÒѾÓÐ0È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ234È˻ظ´
ÄÔ¹£ÔõôÖÎÁÆ
ÒѾÓÐ3È˻ظ´
ÄÔ¹£ÔõôÖÎÁÆ
ÒѾÓÐ0È˻ظ´
ÉúÎï×éÖ¯ÖÐÓÐÄ¿±ê·ÖÎöÎרÊôÐÔÔõô×ö
ÒѾÓÐ0È˻ظ´
bqchen
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 1605.4
- É¢½ð: 50
- ºì»¨: 3
- Ìû×Ó: 289
- ÔÚÏß: 54.3Сʱ
- ³æºÅ: 448346
- ×¢²á: 2007-11-01
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É
4Â¥2016-06-02 11:03:47
bqchen
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 1605.4
- É¢½ð: 50
- ºì»¨: 3
- Ìû×Ó: 289
- ÔÚÏß: 54.3Сʱ
- ³æºÅ: 448346
- ×¢²á: 2007-11-01
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É
|
ŵ·úɳÐÇBCS·ÖÀàΪ 4Àࣺ ²Î¿¼ÎÄÏ×£ºSolubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives. Susana A. Breda, Alvaro F. International Journal of Pharmaceutics,Volume 371, Issues 1¨C2, 17 April 2009, Pages 106¨C113£º the active pharmaceutical ingredients (APIs) currently used in solid dosage forms, norfloxacin and ciprofloxacin hydrochloride, proved to be BCS class 4 (low solubility/low permeability). |
2Â¥2016-06-01 10:30:39














»Ø¸´´ËÂ¥